Biocryst Pharmaceuticals Stock
Price
Target price
€5.22
€5.22
1.130%
0.056
1.130%
€11.05
13.05.24 / Tradegate
WKN: 896047 / Symbol: BCRX / Name: Biocryst Pharm / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Biocryst Pharmaceuticals Stock
There is an upward development for Biocryst Pharmaceuticals compared to yesterday, with an increase of €0.056 (1.130%).
With 9 Buy predictions and not the single Sell prediction the community is currently very high on Biocryst Pharmaceuticals.
Based on the current price of 5.22 € the target price of 11 € shows a potential of 110.57% for Biocryst Pharmaceuticals which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Biocryst Pharmaceuticals stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Biocryst Pharmaceuticals in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Biocryst Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals | 1.130% | 19.971% | 10.136% | -35.406% | -10.661% | -52.255% | -29.149% |
| Ardelyx Inc. | 2.910% | -10.646% | 8.836% | 81.814% | 24.879% | 28.893% | - |
| Evolus Inc | -1.690% | -4.065% | 6.306% | 28.261% | 30.387% | 71.014% | - |
| Salarius Pharmaceuticals Inc. | -2.300% | -4.405% | 6.373% | -60.901% | -21.802% | -98.210% | -99.992% |
Comments
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat